Genmab — Maj 2019
-
Man kan vel også spille på flere heste i stedet for at satse det hele på en som i perioder er lidt bovlam.
-
Du må stoppe med at lukke så meget l... ud.
-
Sorry...Den lå lige til højrebenet.
-
-
And I think we could potentially see partnerships for both of these programs to maximize the potential for the CD3xCD20, the very competitive hematological area. Now a little bit behind Roche and Regeneron but with a very differentiated molecule. This is given subcutaneously and preclinically. It's very, very much more potent than these other programs and we use a different way of silencing the bispecific. So we expect potentially less side effect issues than had been seen with this earlier
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind